Capricor Therapeutics, Inc.

Organization

Capricor Therapeutics is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapies. Its lead candidate, deramiocel (CAP-1002), is an allogeneic cardiosphere-derived cell therapy primarily being developed for the treatment of Duchenne muscular dystrophy.